Evidence map›Paper›PMID 35597134›Full record

ArticleSchizophrenia research2022

Three prominent self-report risk measures show unique and overlapping utility in characterizing those at clinical high-risk for psychosis.

Trevor F Williams, Albert R Powers, Lauren M Ellman, Philip R Corlett, Gregory P Strauss, Jason Schiffman, James A Waltz, Steven M Silverstein, Scott W Woods, Elaine F Walker and 2 more

Open access · greenAbstract read
In one paragraph

Article in Schizophrenia research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Trevor F WilliamsDepartment of Psychology, Northwestern University, Evanston, IL 60208, USA. Electronic address: trevor.williams@northwestern.edu.
Albert R PowersDepartment of Psychiatry, Yale University, New Haven, CT 06519, USA.
Lauren M EllmanDepartment of Psychology, Temple University, Philadelphia, PA 19122, USA.
Philip R CorlettDepartment of Psychiatry, Yale University, New Haven, CT 06519, USA.
Gregory P StraussDepartments of Psychology and Neuroscience, University of Georgia, Athens, GA, 30602, USA.
Jason SchiffmanDepartment of Psychological Science, 4201 Social and Behavioral Sciences Gateway, University of California, Irvine, CA 92697, USA.
James A WaltzMaryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA.
Steven M SilversteinDepartments of Psychiatry, Neuroscience and Ophthalmology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Scott W WoodsDepartment of Psychiatry, Yale University, New Haven, CT 06519, USA.
Elaine F WalkerDepartment of Psychology and Program in Neuroscience, Emory University, Atlanta, GA 30322, USA.
James M GoldMaryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA.
Vijay A MittalInstitutes for Policy Research (IPR) and Innovations in Developmental Sciences (DevSci), Departments of Psychology, Psychiatry, Medical Social Sciences, Northwestern University, Evanston, IL 60208, USA.
Yale University · USNorthwestern University · USUniversity of Maryland, Baltimore · USEmory University · USTemple University · USUniversity of California, Irvine · USUniversity of Georgia · USUniversity of Rochester Medical Center · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
2/9 - Predictors and Mechanisms of Conversion to PsychosisU01MH081988 · NIMH · EMORY UNIVERSITY · PI WALKER, ELAINE FRAN · 2008 to 2018
$5.4M
5/5 CAPER: Computerized Assessment of Psychosis RiskR01MH120089 · NIMH · YALE UNIVERSITY · PI CORLETT, PHILIP, WOODS, SCOTT W · 2020 to 2024
$3.1M
Prodromal Inventory for Negative Symptoms (PINS): A Development and Validation StudyR01MH116039 · NIMH · UNIVERSITY OF GEORGIA · PI MITTAL, VIJAY A, STRAUSS, GREGORY P · 2019 to 2023
$3.1M
1/5 CAPER: Computerized Assessment of ProdromE RiskR01MH120090 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI GOLD, JAMES M. · 2020 to 2024
$2.9M
4/5 CAPER: Computerized assessment of psychosis riskR01MH120092 · NIMH · UNIVERSITY OF GEORGIA · PI STRAUSS, GREGORY P · 2020 to 2024
$2.0M
2/5 CAPER Computerized assessment of psychosis riskR01MH120088 · NIMH · NORTHWESTERN UNIVERSITY · PI MITTAL, VIJAY A · 2020 to 2024
$2.0M
1/3-Community Psychosis Risk Screening: An Instrument Development Study SupplementR01MH112613 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI ELLMAN, LAUREN M · 2017 to 2022
$1.8M
CAPER: Computerized Assessment of Psychosis Risk SupplementR01MH120091 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI ELLMAN, LAUREN M · 2020 to 2024
$1.6M
Administrative Supplement - 3/3: Community Psychology Risk Screening: An Instrument Development StudyR01MH112612 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI PITTS, STEVEN C, SCHIFFMAN, JASON E · 2017 to 2022
$1.3M
2/3 Community psychosis risk screening: An instrument development studyR01MH112545 · NIMH · NORTHWESTERN UNIVERSITY · PI MITTAL, VIJAY A · 2017 to 2021
$1.2M
Exercise and markers of medial temporal health in youth at-risk for psychosisR33MH103231 · NIMH · NORTHWESTERN UNIVERSITY · PI BRYAN, ANGELA, MITTAL, VIJAY A · 2016 to 2018
$689k
NCATS NIH HHS UL1 TR001863NIMH NIH HHS R01 MH112545NIMH NIH HHS R01 MH112612NIMH NIH HHS R01 MH112613NIMH NIH HHS R01 MH116039NIMH NIH HHS R01 MH120088NIMH NIH HHS R01 MH120089NIMH NIH HHS R01 MH120090NIMH NIH HHS R01 MH120091NIMH NIH HHS R01 MH120092NIMH NIH HHS R21 MH103231NIMH NIH HHS R21 MH110374NIMH NIH HHS R21 MH119438NIMH NIH HHS R33 MH103231NIMH NIH HHS U01 MH081988
6 · The paper itself

Abstract

Self-report questionnaires have been developed to efficiently assess psychosis risk and vulnerability. Despite this, the validity of these questionnaires for assessing specific positive symptoms in those at clinical high risk for psychosis (CHR) is unclear. Positive symptoms have largely been treated as a uniform construct in this critical population and there have been no reports on the construct validity of questionnaires for assessing specific symptoms. The present study examined the convergent, discriminant, and criterion validity of the Launay Slade Hallucination Scale-Revised (LSHS-R), Prodromal Questionnaire-Brief (PQB), and Community Assessment of Psychic Experiences positive scale (CAPE-P) using a multimethod approach. CHR individuals (N = 71) and healthy controls (HC; N = 71) completed structured clinical interviews, self-report questionnaires, and neuropsychological tests. Questionnaire intercorrelations indicated strong convergent validity (i.e., all rs > .50); however, evidence for discriminant validity was more variable. In examining relations to interviewer-assessed psychosis symptoms, all questionnaires demonstrated evidence of criterion validity, though the PQB showed the strongest convergent correlations (e.g., r = .48 with total symptoms). In terms of discriminant validity for specific positive symptoms, results were again more variable. PQB subscales demonstrated limited specificity with positive symptoms, whereas CAPE-P subscales showed some specificity and the LSHS-R showed high specificity. In addition, when correlations with internalizing and externalizing symptoms were examined, only the PQB showed consistent significant correlations. These results are interpreted in terms of the strengths and limitations of each measure, their value for screening, and their potential utility for clarifying differences between specific positive symptoms.

Indexed as

Psychotic DisordersHallucinationsHumansNeuropsychological TestsPsychometricsReproducibility of ResultsSelf ReportSurveys and QuestionnairesClinical high riskConstruct validityPositive symptomsQuestionnaires

Identifiers

PMID35597134
PMCPMC9829103
OpenAlexW4280530654

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.